Predict your next investment

CONSUMER PRODUCTS & SERVICES
granderdistro.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Grander Distribution

Grander Distribution specializes in e-liquid products. The company manufactures, markets, and wholesales in all 50 states and in countries worldwide. The company's brands are Naked Fish and Mello Buddha e-liquids.

Grander Distribution Headquarter Location

2200 NW Corporate Blvd 110

Boca Raton, Florida, 33431,

United States

305-363-2216

Latest Grander Distribution News

TerrAscend Completes Acquisition of Grander Distribution, a US Hemp-Derived Products Company

Jan 15, 2019

News provided by Share this article TORONTO, Jan. 15, 2019 /CNW/ - TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) ("TerrAscend") today announced the closing of the previously reported asset acquisition of Grander Distribution, LLC ("Grander"). Grander is an industry leader in the production and distribution of innovative hemp-derived wellness products. Their whole-plant hemp extract products are made in the USA and are available for sale in ~10,000 retail locations worldwide. About TerrAscend Corp. TerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. TerrAscend provides support to patients and consumers through its wholly-owned subsidiaries, TerrAscend Canada Inc., a licensed producer of cannabis pursuant to the Cannabis Regulations under the Cannabis Act (Canada) that provides medical cannabis to patients through its online medical marketplace Solace Health, and Solace Health Network Inc., a clinical support program and education platform led by healthcare professionals. TerrAscend participates in the legal adult-use market in Canada through direct and indirect supply agreements in several provinces and the US market in states where cannabinoids have been legalized for therapeutic or adult-use. TerrAscend, in partnership with leading researchers Cistron Corp, launched Ascendant Labs, a biotechnology and licensing company committed to the continuous improvement of cannabinoid expressing plants. Caution Regarding Cannabis Operations in the United States Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to cultivate, distribute or possess cannabis in the United States. Furthermore, financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation. While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. Following any investment made by TerrAscend in operations in the United States, enforcement of federal laws in the United States will be a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance. SOURCE TerrAscend For further information: regarding TerrAscend: Michael Nashat, Chief Executive Officer, IR@terrascend.com; Adam Kozak, Chief Financial Officer, IR@terrascend.com, 1-855-837-7295 ext. 2 Also from this source

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.